Helix BioPharma Corp. (HBPCF)
Sector: Biotechnology
Industry: Biotechnology
Helix BioPharma Corp.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | 1.71 | 1.71 | 0.7700 | 0.7700 | 100 |
| Nov 13, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Nov 12, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Nov 11, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Nov 10, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Nov 9, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Nov 6, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Nov 5, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Nov 4, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Nov 3, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Oct 30, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Oct 29, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Oct 28, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Oct 27, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Oct 26, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Oct 23, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Oct 21, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Oct 20, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Oct 19, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
| Oct 16, 2026 | 0.7700 | 0.7700 | 0.7700 | 0.7700 | 100 |
Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology.
The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to interact with vascular epithelial growth factor receptor 2 (VEGFR2). Helix has established collaborative agreements to further its research. One such partnership with Moffitt Cancer Center involves studying L-DOS47's pharmacodynamics and exploring the advantages of co-administering it with immune checkpoint inhibitors. A separate collaboration with University Hospital Tuebingen focuses on evaluating L-DOS47's therapeutic impact on CEACAM6-positive cancer models, employing advanced preclinical metabolic imaging techniques.
The company's corporate headquarters are located in Toronto, Canada.
based on 169.62M shares outstanding
30d Avg
--
60d Avg
200
90d Avg
200